Related Experiment Videos
Tamoxifen-induced tumor stimulation and withdrawal response
Cancer Treatment Reports
|November 1, 1979
Summary
Tamoxifen may unexpectedly accelerate breast cancer growth, increasing tumor doubling time. Following treatment cessation, a significant hormone withdrawal regression may occur, necessitating careful timing for subsequent therapies.
Area of Science:
- Oncology
- Pharmacology
- Endocrinology
Background:
- Tamoxifen is a widely used selective estrogen receptor modulator (SERM) for breast cancer treatment.
- Understanding the full spectrum of tamoxifen's effects on tumor kinetics is crucial for optimizing patient care.
Observation:
- A postmenopausal breast cancer patient with lung metastasis exhibited accelerated tumor growth during tamoxifen therapy.
- Tumor doubling time decreased from 140 days (spontaneous growth) to 52 days (tamoxifen therapy), indicating a nearly threefold increase in growth rate.
Findings:
- Tamoxifen administration resulted in a significant enhancement of tumor growth rate.
- This tumor-stimulating effect persisted for at least one month after tamoxifen discontinuation.
- A subsequent hormone withdrawal regression of the tumor was observed, lasting over six months.
Implications:
- Clinicians should be aware of tamoxifen's potential to stimulate tumor growth, especially in patients with measurable metastatic disease.
- The prolonged activity of tamoxifen necessitates consideration of a sufficient interval between cessation and the initiation of alternative treatments to account for potential withdrawal effects.
- Hormone withdrawal regression following tamoxifen therapy is a significant phenomenon that requires further investigation and clinical consideration.